TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
ESPR

Esperion Therapeutics Inc

Healthcare · Drug Manufacturers - Specialty & Generic

3.20$ +0.0% vs. previous close Closing price · As of: Jul 15, 2026

Statements

Income Statement

Esperion Therapeutics Inc (ESPR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Revenue" came in at 80 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement ESPR
Line item Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 LTM
26 34 32 138 74 52 69 65 82 87 168 80 418
6.8 13 11 10 16 17 26 32 29 55 28 35 146
19 21 21 128 58 34 43 33 54 32 141 46 272
22 15 18 13 11 10 11 13 7.2 14 14 9.0 44
41 33 30 42 44 40 11 43 40 42 41 43 166
56 48 63 55 56 50 48 56 47 42 55 52 196
-37 -28 -42 72 2.6 -16 -4.4 -22 7.1 -10.0 85 -6.6 76
15 15 15 14 14 15 16 19 20 22 23 20 85
-50 -41 -56 61 -62 -30 -21 -40 -13 -31 64 -25 -5.6
-0.1 0.0 -27 0.0 -30 1.8
-50 -41 -56 61 -62 -30 -21 -40 -13 -31 62 -25 -7.4
-35 -26 -41 75 -48 -14 -4.9 -21 7.8 -9.3 86 -45 40

LTM = last twelve months (sum of the four most recent quarters).

Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?